Vaximm AG Shortens Exclusivity Period with BCM Europe to Enhance Licensing Negotiations Vaximm AG announces an updated term sheet with BCM Europe, reducing the exclusivity period to three months to expedite licensing negotiations for its cancer immunotherapy.

Vaximm AG Shortens Exclusivity Period with BCM Europe to Enhance Licensing Negotiations #United_States #Bellevue #VXM01 #Vaximm_AG #BCM_Europe

Vaximm AG Partners with BCM Europe for VXM01 Licensing: A $20M Deal In a significant development, Vaximm AG has entered a $20M term sheet with BCM Europe to explore a potential licensing agreement for VXM01.

Vaximm AG Partners with BCM Europe for VXM01 Licensing: A $20M Deal #None #VXM01 #Vaximm_AG #BCM_Europe